Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer

14 Aug 2021

Abstract excerpt

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations will inevitably develop drug resistance after being treated with the third-generation EGFR-tyrosine kinase inhibitor (TKI), osimertinib. Recently, the drug resistance information transmitted by exosomal miRNAs has attracted much attention. However, the mechanism of exosome-derived miRNAs in osimertinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular vesicles in disease
Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34391435
DOI: 10.1186/s12935-021-02075-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancerPMID 34391435Read ↗

Elevated Exosome-derived Mirnas Predict Osimertinib Resistance in Non-small Cell Lung CancerSemantic proximity Read ↗

Exosomes miR-184 and miR-3913-5p are involved in Osimertinib resistance in non-small cell lung cancer patients with exon 21 L858R mutationSemantic proximity Read ↗

Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patientsSemantic proximity Read ↗

Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.Semantic proximity Read ↗

Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation.Semantic proximity Read ↗

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.Semantic proximity Read ↗

Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell linesSemantic proximity Read ↗

MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinomaSemantic proximity Read ↗

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.